Brain Cancer

Laser-Based Imaging + AI May Diagnose Brain Tumors in OR

Publish Date January 14, 2020

Accurate diagnosis in <150 seconds in the operating room could improve decision-making during surgery.

Strategies for Managing Postradiotherapy Cerebral Radiation Necrosis in Nontarget Brain Tissue

By

Bryant Furlow

Publish Date December 11, 2019

This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.

The Disappointing Reality of Crowdfunding Cancer Care

By

Sarah Elizabeth Richards

Publish Date October 22, 2019

If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.

Some Targeted Therapies May Miss the Mark

By

Caroline Seydel

Publish Date October 17, 2019

Ten different drugs continued to kill cancer cells even when their target proteins were removed.

Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma

By

Devona Williams, PharmD, BCOP

Publish Date September 25, 2019

A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.

Brain Cancer Clinical Trials

Brain Cancer Treatment Regimens

View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.

Patient-Driven Solutions May Lead to Greater Metastatic Breast Cancer Clinical Trial Participation

More patients living with metastatic breast cancer reportedly would be willing to participate in clinical trials if some changes were made.

Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib in the Phase II NP28673 and NP28761 Studies

[Lung Cancer: Targets and Therapy] Data from two phase 2 studies, NP28673 and NP28761, suggest that patients with previously treated ALK-positive NSCLC experienced rapid time to systemic response and time to CNS response with alectinib.

ONA Interview: Immunotherapy Shows Potential in Several Types of Breast Cancer

ONA talked with Adam M. Brufsky, MD, on promising studies from ESMO Congress 2019 on the use of immunotherapy in HR+, HER2– and metastatic triple-negative breast cancers.

Higher Comorbidities Not Likely to Blame for Underrepresentation of African Americans in Clinical Trials, Studies of Acute Myeloid Leukemia

Researchers sought to determine if presence of comorbidities influences the underrepresentation of African American patients with acute myeloid leukemia in clinical trials.